Since you are posting here gross misinformation, I'll repost my assessment of OCLR based on its latest Form10-Q. Actual annual revenues of OCLR are less than $440 M. Share count is 107.7 M. Cash by now is much less than $141 M. The company is and will be unprofitable for at least a year. HLIT is profitable, has fewer shares outstanding, has more cash and growing, and it is getting more and more into software and services. OCLR is in a cutthroat hardware component business.
Cash: ended 2013 with $142M but "Regarding our cash, we expect further cash usage this calendar year in the following four areas. One, to fund our remaining restructuring; two, to fund negative adjusted EBITDA; three, to normalize our AP post-divestiture, which we expect we will require $25 million to $30 million in cash; and four, to fund normal CapEx and capital lease payments of approximately $4 million to $5 million per quarter." What this means? Unless there is another asset sale, Oclaro will likely end 2014 with $40 to $50M and still not profitable.
Share count: in the earnings release the share count was stated as 93.2M. In reality, the current share count is 107.7M. "As previously announced we exchanged our convertible debt on December 19th. In exchange for $25 million of notes, we issued 13.5 million shares of common stock and paid a make-whole provision of $8.3 million for the remaining four plus years of interests. As a result of the exchange at the end of the quarter, we had shares outstanding of 107.7 million."
Oclaro to Demonstrate a 100G Coherent CFP2 Pluggable Module at OFC 2014; Leverages Indium Phosphide Photonic Integration Leadership
New Coherent Pluggable Product Delivers Increased Density, Lower Power Consumption and Unrivalled Levels of Flexibility for 100G Metro and Long-Haul Networks
amel, i'll keep an eye on it thanks.
you should check out gale in the biotech area, breast cancer & extreme pain drugs. GALE should bounce a lot higher after earnings next week.
Short attacked by Cramer and his cronies from $7.75, so 50% haircut over the last month.
ceil I have been in and out of FCEL for years, in the last few months have made thousands.On this last run-up sold all my shares between $1.95-2.00 ,in hind sight to early.Was hoping for a pullback today (Ukraine) to jump back in at around $1.70.This easily should be in the $3.00 to $5.00 range, but has been a great stock to play dips and runs. This time may be different it is getting good hype, so may run faster than I can get back in.You should look at EFOI this is where I put profit from FCEL it should take off soon to $3.50(look at competitor RVLTfor comparison) .I currently own 200,000 + shares of EFOI .I also bought more OCLR to cost average down still under here(though not for long).Own BIOL, LQMT, back in FCEL soon.
I sold some at $2.88 last week and rebought the same (and more) shares at $2.77 today. The Putin red tag sale worked to my benefit.
I use to own HLIT so I am familiar with the company. I agree with your assessment of where OCLR is valued and where it may go. In fact I am thinking of adding to my shares of OCLR to bring my cost basis down. Don't know whether I should wait until after FNSR reports on Thursday to add.
First of all, OCLR revenue is more like $400 now and HLIT is actually profitable at their current revenue level and OCLR is still losing money. OCLR WILL be $6 once they get their expense and become profitable like HLIT. So, it's somewhat appropriately priced at the moment though with a positive forward-looking view.
There are many similarities except share price. OCLR revenue - 577 million - cash 141 million - shares outstanding 106 million. HLIT revenue- 461 million - cash 170 million - shares outstanding - 99 million . Now share price OCLR $2.82 and HLIT $6.49. In my opinion, OCLR is undervalued at this share price. It should be trading above $6.00.
What it appears to be is that 20K were sold under a fixed-interval trading plan that he set up last year which makes the trade essentially cleared from any insider knowledge however it also appears that he exercised 5266 stock options at the same time - not sold - but exercised, to acquire the stock at $1.36. Granted, the exercise price is miniscule but the fact that he exercised could be his "insider" way of showing support for the upcoming earnings.